Skip to main content
An official website of the United States government

betibeglogene autotemcel

A preparation of autologous, CD34-positive hematopoietic stem cells (HSCs) transduced ex vivo with the BB305 recombinant replication-defective, self-inactivating lentiviral vector encoding for an engineered form of human beta-globin (hemoglobin-beta, HBB) gene, beta-A-T87Q (b-A-T87Q) where the threonine at position 87 has been substituted with glutamine, with potential to restore beta-globin expression and function. Autologous CD34-positive stem cells are isolated from the patient's own bone marrow and the cells are transduced with the lentiviral vector. Upon re-infusion of betibeglogene autotemcel back into the patient, these cells express b-A-T87Q-globin, thereby allowing the body to make normal hemoglobin and thus normal, healthy red blood cells. Beta-globin, the beta-chain of the most common form of hemoglobin, is encoded by the HBB gene; mutations in this gene prevent normal beta-globin production and are associated with beta-thalassemia and sickle cell anemia. The b-A-T87Q form of beta-globin has increased antisickling activity compared to the wild type protein.
Synonym:autologous CD34+ cells encoding beta-A-T87Q-globin gene
autologous CD34+ hematopoietic stem cells transduced ex vivo with betibeglogene darolentivec
autologous CD34+ HSCs transduced with LentiGlobin BB305
LentiGlobin BB305 drug product for TDT
LentiGlobin BB305 lentiviral vector-transduced autologous CD34+ HSCs
LentiGlobin BB305-transduced CD34-positive cells
LentiGlobin drug product for transfusion dependent beta-thalassemia
lentiviral b-A(T87Q)-globin-transduced CD34-positive cells
US brand name:LentiGlobin BB305 Drug Product
Zynteglo
Search NCI's Drug Dictionary